[Use of zoledromic acid on pain control in stages M1b of prostate cancer].
OBJECTIVE
To probe the use of Zoledromic acid in the control of the pain due to bone methastasis of a prostate cancer.


METHODS
We included in our study 37 consecutive patients diagnosed of prostate cancer who developed bone methastasis during 2005 and 2006 to whom we gave a 4 mg dose of Zoledromic acid during a mean time of 10.24 months.


RESULTS
We observed a complete control of the pain in 8 of the 20 patients, and partially in 6 of those patients. We did not evaluate any adverse reaction due to this treatment.


CONCLUSIONS
We still yet to know whether the administration of this treatment in the early stages of the prostate cancer could prevent or retard the appearance of bone methastasis.
Alvarez-Múgica
M
M
Servicio de Urología 1, Hospital Universitario Central de Asturias, Oviedo, Asturias. malvarezmug@gmail.com
Fernández Gómez
J M
JM
Jalón Monzón
A
A
González Alvarez
R C
RC
García Rodríguez
J
J
Martín Benito
J L
JL
D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications* / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D011471:Prostatic Neoplasms / Q000473:pathology; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid